Precision medicine platform to aid multiple myeloma efforts
A new data platform for the Multiple Myeloma Research Foundation aims to aggregate data to accelerate the delivery of precision medicine to patients with the disease.A new data platform for the Multiple Myeloma Research Foundation aims to aggregate data to accelerate the delivery of precision medicine to patients with the disease.
The platform, called CureCloud, went live on June 12. Funding comes from the Broad Institute, and the foundation is working with a number of entities that include COTA, (advanced analytics), Tempus (precision medicine), EMSI Health (risk adjustment services), Prometheus Research (research management tools) and PierianDx (a developer of precision medicine programs).
Multiple myeloma is a cancer of the plasma and is the second most common blood cancer. An estimated 30,000 adults will be diagnosed with the disease this year, and about 12,700 will die. The five-year survival rate is 47 percent.
To fight the disease, substantial amounts of genomic, immune and clinical data needs to be curated and shared by physicians, researchers and patients to drive more effective treatments.
“One of the biggest problems that exists within today’s healthcare system is a lack of access to significant quantities of high-quality longitudinal patient data,” says Kathy Giusti, co-founder and chief mission officer of the foundation. “One of the first steps in achieving this goal is to take on the near-impossible task of bringing together genomic data, immune data and electronic health records across a wide variety of patients to create the CureCloud platform,” says Giusti, who has multiple myeloma.
The CureCloud platform will include the foundation’s CoMMpass study, which it contends is the largest genomic data set of any cancer type and identifies 12 unique sub-types within myeloma, as well as other foundation legacy assets and external data sources.
Further, the Multiple Myeloma Research Foundation will provide access to this data to every stakeholder in the multiple myeloma ecosystem, according to Giusti. A suite of analytics and visualization tools will enable patients and physicians to compare clinical and genomic data with patients in the CureCloud platform to help inform treatment decisions and identify new targets and generate hypotheses.
“This is an exceptionally complex and demanding goal,” acknowledges Steve Labkoff, MD, chief data officer of the foundation.
In the fall, the foundation will launch a patient registry to support the sharing clinical and genomic data, and eventually immunology data.